Loading...
Loading...
AMRX| Name | Value |
|---|---|
| Revenues | 599.0M |
| Cost of Revenue | 379.0M |
| Gross Profit | 220.0M |
| Operating Expense | 144.2M |
| Operating I/L | 80.1M |
| Other Income/Expense | -50.4M |
| Interest Income | 50.9M |
| Pretax | 29.7M |
| Income Tax Expense | -0.0M |
| Net Income/Loss | 11.9M |
Amneal Pharmaceuticals, Inc. develops, manufactures, and distributes generic and specialty pharmaceutical products across various therapeutic areas. The company's Generics segment focuses on complex oral solids, injectables, ophthalmics, and other dosage forms. Its Specialty segment promotes and sells branded pharmaceuticals for central nervous system disorders, endocrinology, and parasitic infections. Additionally, the company's AvKARE segment provides pharmaceuticals, medical and surgical products, and services to governmental agencies. Amneal Pharmaceuticals sells its products through wholesalers, distributors, hospitals, and pharmacies in the United States, India, Ireland, and internationally.
